TABLE 4

Estimated parameter values for fm for DDI cases

The table only includes DDI cases for which the inclusion of substrate metabolite information improved the geometric CV (Fig 3A). Parameter estimates represent summary statistics of 30 parameter sets reproducing concentration–time profiles (low SSlog,time). Refer to Table 2 for details of DDI information with corresponding ID number.

SubstratesInhibitorsIsoforms for ParametersID NumberGeometric MeanGeometric CV
(%)
DesipramineFluoxetineCYP2D62a0.9950.578
3b0.9590.543
FentanylFluconazoleCYP3A40.4729.59
VoriconazoleCYP3A50.73212.8
FlurbiprofenFluconazoleCYP2C960.9457.99
70.9645.91
HydrocodoneQuinidineCYP2D680.51227.7
ImipramineFluoxetineCYP2D69a0.6973.26
10b0.7521.32
LansoprazoleClarithromycinCYP3A13c0.31813.6
14d0.4838.46
15e0.66223.4
OxycodoneQuinidineCYP2D6200.2536.44
VoriconazoleCYP3A210.8261.23
ItraconazoleCYP3A220.8454.35
ParoxetineCYP2D6230.18421.5
RopivacaineItraconazoleCYP3A240.3386.16
  • CV, coefficient of variation.

  • a Fluoxetine single dose.

  • b Fluoxetine multiple dose.

  • c CYP2C19 extensive metabolizer (EM).

  • d CYP2C19 intermediate metabolizer (IM).

  • e CYP2C19 poor metabolizer (PM).